CONNECT BIOPHARMA HOLDINGS L
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About CNTB
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
Find out what a historical investment in CONNECT BIOPHARMA HOLDINGS L would be worth today using our CNTB stock calculator.
$141.99M
-
0.00%
55.53K
$2.55
$2.40
$2.55
$3.28
$0.51
Ready to start your investing journey with Stake?
Open an accountCNTB FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in CNTB
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in CNTB
on Stake
Buy CNTB from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of CNTB from only US$10 with fractional shares
